Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Natalia Mena-VázquezMarta Rojas-GimenezClara Fuego-VarelaAimara García-StuderNair Perez-GómezCarmen María Romero-BarcoFrancisco Javier Godoy-NavarreteSara Manrique-ArijaMyriam Gandía-MartínezJerusalem Calvo-GutiérrezPilar Morales-GarridoCoral Mouriño-RodriguezPatricia Castro-PérezIsabel Añón-OñateFrancisco EspildoraMaría Carmen Aguilar-HurtadoAna Hidalgo CondeRocío Arnedo Díez de Los RíosEva Cabrera CésarRocío Redondo-RodriguezMaría Luisa Velloso-FeijooAntonio Fernandez-Nebro

Published in: Biomedicines (2022)

Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile.

Keyphrases

interstitial lung disease
rheumatoid arthritis
systemic sclerosis
disease activity
ankylosing spondylitis
oxidative stress
randomized controlled trial
rheumatoid arthritis patients
idiopathic pulmonary fibrosis
systematic review
newly diagnosed